ANMCO声明:在心脏-脏-代谢连续体中含有西马格卢提德
Leonardo De Luca1, Claudio Bilato2, Alessandro Navazio3
1S.C. Cardiologia, Dipartimento Cardio-Toraco-Vascolare, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
概括
塞马格卢提德 (Semaglutide) 通过改善心脏和脏健康,超出血糖控制的范围,有利于2型糖尿病患者. 这种药物有助于减少心血管事件,并减缓脏疾病的进展.
科学领域:
- 药理学和内分泌学 药理学和内分泌学
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 赛马格卢提德是一种GLP-1受体激活剂,最初用于治疗2型糖尿病.
- 它的治疗范围正在扩大,以解决心脏-脏-代谢连续.
- 肥胖和心血管疾病是与代谢功能障碍相关的重大公共卫生问题.
研究的目的:
- 审查目前关于塞马格卢提德对心血管,脏和代谢健康的多方面的影响的证据.
- 突出塞马格卢提德在治疗心脏-脏-代谢相关疾病的患者中的作用.
主要方法:
- 临床试验和相关文献的系统审查.
- 对心血管结果,功能标志物和代谢参数数据的分析.
- 综合证据关于塞马格卢提德的拟议作用机制.
主要成果:
- 塞马格卢提德显著减少了高心血管风险的超重/肥胖患者的主要心血管不良事件.
- 在心力衰竭中观察到功能能力的改善,其中保留了喷射分数.
- 在糖尿病人群中,积极的结局包括减缓白蛋白尿症进展和降低慢性病风险.
结论:
- 塞马格卢提德在整个心脏-脏-代谢谱中表现出广泛的疗效.
- 它的好处来自减肥,降低血压,抗炎作用和直接的保护.
- 塞马格卢提德代表了对这些相互关联的疾病综合管理的有前途的治疗选择.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Cardiovascular Drugs: Classification based on Therapeutic Indications
1.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
1.9K
Glucagon-like Receptor Agonists
277
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
277
Diabetes: Management and Pharmacotherapy
216
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
216
Oral Hypoglycemic Agents: Biguanides and Glitazones
144
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
144


